CAMBRIDGE: Nuformix plc announced the appointment of Dr Anne Brindley as Chief Executive Officer “CEO” and Executive Director of the Company with immediate effect.

Anne has over 30 years’ experience in Big Pharma, Biotech and smaller R&D companies, with a proven international track record of leading organisations through strategic change and driving projects and portfolios through discovery and development to market.

Anne was previously CEO of Advent Pharmaceuticals Pty Ltd, Melbourne, Australia, a specialty R&D company focused on generic inhaled products for global markets. In that role, Anne led a successful sale of the products and assets to AuroScience Pty Ltd, Melbourne, Australia, a wholly owned subsidiary of Aurobindo Pharma USA Inc. She subsequently became CEO of AuroScience Pty Ltd.

Before moving to Advent, Anne was a Board member and Managing Director of Respivert Ltd, a subsidiary of Janssen Pharmaceuticals (part of Johnson & Johnson, Inc), where she was responsible for leadership and operations of the company, including discovery / development programmes spanning three novel classes of drug for idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and asthma, as well as out-licensing activities. Prior to this, Anne occupied the role of Vice President and Head of Inhalation Products.

Anne’s earlier career included roles as Executive Vice President, Pharmaceutical Development & Project Management at Skyepharma plc, a specialty pharma company developing innovative oral and inhalation products, and senior positions in Product Development at AstraZeneca PLC. Prior to this, Anne worked at GlaxoSmithKline plc.

Dr Chris Blackwell, Non-Executive Chairman, commented: “I am delighted to welcome Anne as the CEO of Nuformix. Anne has extensive expertise in small molecule R&D spanning discovery, early and late stage development, through to registration and commercialisation in respiratory and oncology therapy areas for both innovator and generic products. She is a renowned expert in inhaled products and drug/device combinations. This wealth of relevant experience coupled with her leadership and Board experience will help the Company move forward with its strategic priorities. I now look forward to working with Anne and the rest of the Board as I resume the role of Non-Executive Chairman.”

Commenting on her appointment, Dr Anne Brindley said: “I am delighted to have accepted the role of CEO of Nuformix at this important time for the Company. I look forward to driving the business strategy and achieving the Company’s objectives. Having worked in the pharma industry for over 30 years, I can see that Nuformix has assets and technology that have great potential and I intend to work with the Board to take these forward in development.”

Nuformix is a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop new novel medicines which provide therapeutic and commercial advantages to the currently available drug form.

Nuformix’s model of repurposing drugs utilises many technologies but is focussed on its acknowledged expertise in the use of cocrystal technology through which the Group has developed and patented novel forms of small molecules. Its platform is not therapy-specific but instead has broad application across a wide range of indications. Using its technology, the Group is developing proprietary medicines for its own development pipeline and in partnership with pharmaceutical and biotech companies.

Nuformix plc shares are traded on the London Stock Exchange’s Official List under the ticker: NFX. www.nuformix.com